Molecular ontogeny of major neurotransmitter receptor systems in the mammalian central nervous system: Norepinephrine, dopamine, serotonin, acetylcholine, and glycine

Journal of Child Neurology

Volumn 16, Issue 4, 2001, Pages 271-280

  Rho, Jong M ^a,b   Storey, Thomas W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADRENALIN; ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCIUM ION; CHOLINERGIC RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IONOTROPIC RECEPTOR; LIGAND; METABOTROPIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; RECEPTOR SUBUNIT; SEROTONIN; SEROTONIN RECEPTOR; SODIUM ION;

ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; INFORMATION; ION PERMEABILITY; MAMMAL; MEMBRANE POTENTIAL; MOLECULAR BIOLOGY; NONHUMAN; ONTOGENY; PATHOLOGY; PHARMACOLOGY; PRIORITY JOURNAL; SECOND MESSENGER; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 0035002823     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380101600407     Document Type: Article

References (87)

1. Bennett MR: The concept of transmitter receptors: 100 years on. Neuropharmacology 2000;39:523-546.
2. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology, 7th ed. New York, Oxford University Press, 1996.
3. Kuhar MJ, Couceyro PR, Lambert PD: Catecholamines, in Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds): Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th ed. Philadelphia, Lippincott-Raven, 1999, 243-261.
4. Lander JM, Bloom FE: Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. I. Cell differentiation. J Comp Neurol 1974;155:469-482.
5. Foote SL, Bloom FE, Aston-Jones G: Nucleus locus coeruleus: New evidence of anatomical and physiological specificity. Physiol Rev 1983;63:844-914.
6. Lauder JM, Bloom FE: Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. II. Synaptogenesis. J Comp Neurol 1975;163:251-264.
7. Johnston MV, Coyle JT: Ontogeny of neurochemical markers for noradrenergic, GABAergic, and cholinergic neurons in neocortex lesioned with methylazoxymethanol acetate. J Neurochem 1980;34: 1429-1441.
8. Marshall KC, Christie MJ, Finlayson PG, et al: Developmental aspects of the locus coeruleus-noradrenaline system. Prog Brain Res 1991;88:173-185.
9. Duman RS, Alvaro JD: Developmental expression of adrenergic receptors in the central nervous system, in Zagon IS, McLaughlin PJ (eds): Receptors in the Developing Nervous System, Vol. 2: Neurotransmitters. London, Chapman & Hall, 1993, 1-19.
10. Bruinink A, Liehtensteiger W: β-Adrenergic binding sites in fetal rat brain. J Neurochem 1984;43:578-581.
11. Harden TK, Wolfe BB, Sporn JR, et al: Ontogeny of β-adrenergic receptors in rat cerebral cortex. Brain Res 1977;125:99-108.
12. Morris MJ, Dausse JP, Devynck MA, et al: Ontogeny of α1 and α2-adrenoreceptors in rat brain. Brain Res 1980;190:268-271.
13. Hartley E, Seeman P: Development of receptors for dopamine and noradrenaline in rat brain. Eur J Pharmacol 1983;91:391-397.
14. Vernadakis A, Gibson DA: Role of neurotransmitter substances in neural growth, in Dancis J, Hwang JC (eds): Perinatal Pharmacology: Problems and Priorities. New York, Raven, 1974, 65-76.
15. Konkol RJ, Bendeich E, Breese GR: A biochemical and morphological study of the altered growth pattern of central catecholamine neurons following 6-hydroxydopamine. Brain Res 1978;140: 125-135.
16. Gordon B, Allen EE, Trombley PQ: The role of norepinephrine in plasticity of visual cortex. Prog Neurobiol 1988;30:171-191.
17. Goldstein DS, Eisenhofer G, McCarty R (eds): Catecholamines: bridging basic science with clinical medicine, in Advances in Pharmacology, Vol. 42. London, Academic Press, 1998.
18. Szot P, Weinshenker D, White SS, et al: Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci 1999;19:10985-10992.
19. Ogawa N: Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama 1995;49:1-11.
20. Neve KA, Neve RL: The Dopamine Receptors. Totowa, NJ, Humana, 1997.
21. Tarazi FI, Baldessarini RJ: Comparative postnatal development of dopamine D1, D2 and D4 receptors in rat forebrain. Int J Dev Neurosci 2000;18:29-37.
22. Nair VD, Mishra RK: Ontogenic development of dopamine D4 receptors in the rat brain. Dev Brain Res 1995;90:180-183.
23. Florijn WJ, Tarazi FI, Creese I: Dopamine receptor subtypes: Differential regulation following 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997;280:561-569.
24. Tarazi FI, Florijn WJ, Creese I: Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 1997;78:985-996.
25. Hoyer D, Clarke DE, Fozard JR, et al: International union of pharmacological classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-193.
26. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152.
27. Sugita S, Shen KZ, North RA: 5-Hydroxytryptamine is a fast excitatory transmitter at 5-HT3 receptors in rat amygdala. Neuron 1992; 8:199-203.
28. Lauder JM: Ontogeny of the serotonergic system in the rat: Serotonin as a developmental signal. Ann N Y Acad Sci 1990;600: 297-313.
29. Aitken AR, Törk I: Early development of serotonin-containing neurons and pathways as seen in wholemount preparations of the fetal rat brain. J Comp Neurol 1988;274:32-47.
30. Lidov HG, Molliver ME: An immunohistochemical study of serotonin neuron development in the rat: Ascending pathways and terminal fields. Brain Res Bull 1982;8:389-430.
31. Rajaofetra N, Sandillon F, Geffard M, et al: Pre- and postnatal ontogeny of serotonergic projections to the rat spinal cord. J Neurosci Res 1989;22:305-321.
32. Traber J, Glaser T: 5-HT1A-related anxiolytics. Trends Pharmacol Sci 1987;8:432-437.
33. 1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995; 115:1064-1070.
34. 1A antagonists. Trends Neurosci 1996;19:378-383.
35. Romero L, Hervas I, Artigas F: The 5-HT1A antagonist WAY-100,635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 1996;219: 123-126.
36. Lauder JM, Krebs H: Serotonin as a differentiation signal in early neurogenesis. Dev Neurosci 1978;1:15-30.
37. 1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996;14:35-46.
38. Riad M, Emerit MB, Hamon M: Neurotrophic effects of ipsapirone and other 5-HT1A receptor agonists on septal cholinergic neurons in culture. Brain Res Dev Brain Res 1994;82:245-258.
39. Yan W, Wilson CC, Haring JH: Effects of neonatal serotonin depletion on the development of rat dentate granule cells. Dev Brain Res 1997;98:177-184.
40. Kojic L, Dyck RH, Gu Q, et al: Columnar distribution of serotonin-dependent plasticity within kitten striate cortex. Proc Natl Acad Sci USA 2000;97:1841-1844.
41. Costa LG: Muscarinic receptors and the developing nervous system, in Zagon IS, McLaughlin PJ (eds): Receptors in the Developing Nervous System, Vol. 2: Neurotransmitters. London, Chapman and Hall, 1993, 21-42.
42. Levey AI: Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 1996;93:13541-13546.
43. Shiozaki K, Iseki E, Uchiyama H, et al: Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: Relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:209-213.
44. Costa LG, Guizzetti M: Muscarinic cholinergic receptor signal transduction as a potential target for the developmental neurotoxicity of ethanol. Biochem Pharmacol 1999;57:721-726.
45. Perry E, Walker M, Grace J, et al: Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999;22: 273-280.
46. Bonner TI, Buckley NJ, Young AC, et al: Identifications of a family of muscarinic acetylcholine receptor genes. Science 1987;237: 527-532.
47. Wolfe BB, Yasuda RP: Development of selective antisera for muscarinic cholinergic receptor subtypes. Ann N Y Acad Sci 1995;757: 186-193.
48. Hohmann CF, Pert CC, Ebner FF: Development of cholinergic markers in mouse forebrain. II. Muscarinic receptor binding in cortex. Brain Res 1985;355:243-253.
49. Aubert I, Cecyre D, Gauthier S, et al: Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. J Comp Neurol 1996;369:31-55.
50. Tice MAB, Hashemi T, Taylor LA, et al: Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Dev Brain Res 1996;92:70-76.
51. Lauder JM, Schambra UB: Morphogenetic roles of acetylcholine. Environ Health Perspect 1999;107(Suppl 1):65-69.
52. Buwalda B, de Groote L, Van der Zee EA, et al: Immunocytochemical demonstration of developmental distribution of muscarinic acetylcholine receptors in rat parietal cortex. Dev Brain Res 1995;84:185-191.
53. Liu Y, Jia W, Gu Q, Cynader M: Involvement of muscarinic acetylcholine receptors in regulation of kitten visual cortex plasticity. Dev Brain Res 1994;79:63-71.
54. Schambra UB, Lauder JM, Perusz P, et al: Development of neurotransmitter systems in the mouse embryo following acute ethanol exposure: A histological and immunocytochemical study. Int J Dev Neurosci 1990;8:507-522.
55. Burgess DL, Noebels JL: Single gene defects in mice: The role of voltage-dependent calcium channels in absence models. Epilepsy Res 1999;36:111-122.
56. Liles WC, Taylor S, Finnell R, et al: Decreased muscarinic acetylcholine receptor number in the central nervous system of the tottering (tg/tg) mouse. J Neuroichem 1986;46:977-982.
57. Clarke PBS, Quik M, Adlkofer F, et al (eds): Advances in Pharmacological Sciences, Vol. 2: Effects of Nicotine on Biological Systems. Basel, Switzerland, Birkhauser Verlag, 1995.
58. James JR, Nordberg A: Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet 1995;25:149-159.
59. Barnard E: Receptor classes and the transmitter-gated ion channels. Trends Biochem Sci 1992;17:369-374.
60. Colquhoun LM, Patrick JW: Pharmacology of neuronal nicotinic acetylcholine receptor subtypes, in Advances in Pharmacology, Vol. 39. New York, Academic, 1997, 191-220.
61. Cooper E, Couturier S, Ballivet M: Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991;350:235-238.
62. Whiting PJ, Schoepfer F, Lindstrom J, et al: Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol Pharmacol 1991;40:463-472.
63. Couturier S, Bertrand D, Matter JM, et al: A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-Btx. Neuron 1990;5:847-856.
64. Role LW, Berg DK: Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996;16:1077-1085.
65. Dani JA, Mayer ML: Structure and function of glutamate and nicotinic acetylcholine receptors. Curr Opin Neurobiol 1995;5: 310-317.
66. Smith J, Faquet M, Ziller C, et al: Acetylcholine synthesis by mesencephalic neural crest cells in the process of migration in vivo. Nature 1979;282:853-855.
67. Zoli M, Le Novere N, Hill JA Jr, et al: Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 1995;15:1912-1939.
68. Corriveau RA, Berg DK: Coexpression of multiple acetylcholine receptor genes in neurons: Quantitation of transcripts during development. J Neurosci 1993;13:2662-2671.
69. Pugh PC, Berg DK: Neuronal acetylcholine receptors that bind α-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J Neurosci 1994;14:889-896.
70. Zheng JQ, Felder M, Connor JA, et al: Turning of nerve growth cones induced by neurotransmitters. Nature 1994;368:140-144.
71. Steinlein OK, Mulley JC, Propping P, et al: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-203.
72. Steintein OK, Magnusson A, Stoodt J, et al: An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 1997;6:943-947.
73. Phillips HA, Scheffer IE, Crossland KM, et al: Autosomal dominant nocturnal frontal lobe epilepsy: Genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 1998;63: 1108-1116.
74. 2+ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors. J Neurosci 1997;17:9035-9047.
75. Wevers A, Jeske A, Lobron C, et al: Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Brain Res Mol Brain Res 1994;25:122-128.
76. Schmieden V, Grenningloh G, Schofield PR, et al: Functional expression in Xenopus oocytes of the strychnine binding 48kD subunit of the glycine receptor. EMBO J 1989;8:695-700.
77. Malosio ML, Marquezè-Pouey B, Kuhse J, et al: Widespread expression of glycine receptor subunit mRNAs in the adult rat and developing rat brain. EMBO J 1991;10:2401-2409.
78. Sato K, Zhang JH, Saika T, et al: Localization of glycine receptor al subunit mRNA-containing neurons in the rat brain: An analysis using in situ hybridization histochemistry. Neuroscience 1991; 43:381-395.
79. Becker CM, Hoch W, Betz H: Glycine receptor heterogeneity in rat spinal cord during postnatal development. EMBO J 1988;7: 3717-3726.
80. Hoch W, Betz H, Becker CM: Primary cultures of mouse spinal cord express the neonatal isoform of the inhibitory glycine receptor. Neuron 1990;3:339-348.
81. Aschroft FM: Ion Channels and Disease: Channelopathies. London, Academic Press, 2000.
82. Becker CM, Schmieden V, Tarroni P, et al: Isoform-selective deficit of glycine receptors in the mouse mutant spastic. Neuron 1992;8: 283-289.
83. Kingsmore SF, Giros B, Suh D, et al: Glycine receptor beta-subunit gene mutation in spastic mouse associated with LINE-1 element insertion. Nat Genet 1994;7:136-141.
84. Ryan SG, Dixon MJ, Nigro MA, et al: Genetic and radiation hybrid mapping of the hyperekplexia region on chromosome 5q. Am J Hum Genet 1992;51:1334-1343.
85. Shiang R, Ryan SG, Zhu Y-Z, et al: Mutations in the α1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993;5:351-358.
86. Rajendra S, Lynch JW, Pierce KD, et al: Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists. Neuron 1995; 14:169-175.
87. Rajendra S, Lynch JW, Pierce KD, et al: Startle disease mutations reduce the agonist sensitivity of the human inhibitory glycine receptor. J Biol Chem 1994;269:18739-18742.